Ko Kudo

Dr. Ko Kudo

orcid

Research Focus & Metrics

Academic Career Length

9Years (2018-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
20 June 2024 in Blood
Verified
Journal Article
Closed access
PDF file
TSTomohiko Sato
Tomohiko Sato
KYKenichi Yoshida
Kenichi Yoshida
TTTsutomu Toki
Tsutomu Toki
RKRika Kanezaki
Rika Kanezaki
KTKiminori Terui
Kiminori Terui
EIEtsuro Ito
Etsuro Ito
Transient abnormal myelopoiesis (TAM) is a common complication in newborns with Down syndrome (DS). It commonly progresses to myeloid leukemia (ML-DS) after spontaneous regression. In contrast to the favorable prognosis of primary ML-DS, patients with refractory/relapsed ML-DS have poor outcomes. However, the molecular basis for refractoriness and relapse and the full spectrum of driver mutations in ML-DS remain largely unknown. We conducted a genomic profiling study of 143 TAM, 204 ML-DS, and 34 non-DS acute megakaryoblastic leukemia cases, including 39 ML-DS cases analyzed by exome sequencing. Sixteen novel mutational targets were identified in ML-DS samples. Of these, inactivations of IRX1 (16.2%) and ZBTB7A (13.2%) were commonly implicated in the upregulation of the MYC pathway and were potential targets for ML-DS treatment with bromodomain-containing protein 4 inhibitors. Partial tandem duplications of RUNX1 on chromosome 21 were also found, specifically in ML-DS samples (13.7%), presenting its essential role in DS leukemia progression. Finally, in 177 patients with ML-DS treated following the same ML-DS protocol (the Japanese Pediatric Leukemia and Lymphoma Study Group acute myeloid leukemia -D05/D11), CDKN2A, TP53, ZBTB7A, and JAK2 alterations were associated with a poor prognosis. Patients with CDKN2A deletions (n = 7) or TP53 mutations (n = 4) had substantially lower 3-year event-free survival (28.6% vs 90.5%; P < .001; 25.0% vs 89.5%; P < .001) than those without these mutations. These findings considerably change the mutational landscape of ML-DS, provide new insights into the mechanisms of progression from TAM to ML-DS, and help identify new therapeutic targets and strategies for ML-DS.

17 March 2022 in Haematologica
Verified
Journal Article
Open access
PDF file
KKKo Kudo
Ko Kudo
TTTsutomu Toki
Tsutomu Toki
RKRika Kanezaki
Rika Kanezaki
TTTatsuhiko Tanaka
Tatsuhiko Tanaka
TKTakuya Kamio
Takuya Kamio
EIEtsuro Ito
Etsuro Ito

13 October 2019 in Genes, Chromosomes and Cancer
Verified
Journal Article
Closed access
PDF file
KTKiminori Terui
Kiminori Terui
TTTsutomu Toki
Tsutomu Toki
TTTakashi Taga
Takashi Taga
SIShotaro Iwamoto
Shotaro Iwamoto
TMTakako Miyamura
Takako Miyamura
EIEtsuro Ito
Etsuro Ito

5 February 2020 in Pediatric Blood & Cancer
Verified
Journal Article
Closed access
PDF file
KYKentaro Yuzawa
Kentaro Yuzawa
KTKiminori Terui
Kiminori Terui
TTTsutomu Toki
Tsutomu Toki
RKRika Kanezaki
Rika Kanezaki
AKAkie Kobayashi
Akie Kobayashi
EIEtsuro Ito
Etsuro Ito

21 February 2019 in Pediatrics International
Verified
Journal Article
Closed access
PDF file
KKKo Kudo
Ko Kudo
TTTatsuhiko Tanaka
Tatsuhiko Tanaka
AKAkie Kobayashi
Akie Kobayashi
KTKiminori Terui
Kiminori Terui
EIEtsuro Ito
Etsuro Ito

10 October 2019 in Pediatric Blood & Cancer
Verified
Journal Article
Closed access
PDF file
YTYoshihiro Takahashi
Yoshihiro Takahashi
KTKiminori Terui
Kiminori Terui
YCYoshiaki Chinen
Yoshiaki Chinen
STSatoru Tandai
Satoru Tandai
KKKo Kudo
Ko Kudo
EIEtsuro Ito
Etsuro Ito